TY - JOUR
TI - Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
AU - Moreau, P.
AU - Kumar, S.K.
AU - San Miguel, J.
AU - Davies, F.
AU - Zamagni, E.
AU - Bahlis, N.
AU - Ludwig, H.
AU - Mikhael, J.
AU - Terpos, E.
AU - Schjesvold, F.
AU - Martin, T.
AU - Yong, K.
AU - Durie, B.G.M.
AU - Facon, T.
AU - Jurczyszyn, A.
AU - Sidana, S.
AU - Raje, N.
AU - van de Donk, N.
AU - Lonial, S.
AU - Cavo, M.
AU - Kristinsson, S.Y.
AU - Lentzsch, S.
AU - Hajek, R.
AU - Anderson, K.C.
AU - João, C.
AU - Einsele, H.
AU - Sonneveld, P.
AU - Engelhardt, M.
AU - Fonseca, R.
AU - Vangsted, A.
AU - Weisel, K.
AU - Baz, R.
AU - Hungria, V.
AU - Berdeja, J.G.
AU - Leal da Costa, F.
AU - Maiolino, A.
AU - Waage, A.
AU - Vesole, D.H.
AU - Ocio, E.M.
AU - Quach, H.
AU - Driessen, C.
AU - Bladé, J.
AU - Leleu, X.
AU - Riva, E.
AU - Bergsagel, P.L.
AU - Hou, J.
AU - Chng, W.J.
AU - Mellqvist, U.-H.
AU - Dytfeld, D.
AU - Harousseau, J.-L.
AU - Goldschmidt, H.
AU - Laubach, J.
AU - Munshi, N.C.
AU - Gay, F.
AU - Beksac, M.
AU - Costa, L.J.
AU - Kaiser, M.
AU - Hari, P.
AU - Boccadoro, M.
AU - Usmani, S.Z.
AU - Zweegman, S.
AU - Holstein, S.
AU - Sezer, O.
AU - Harrison, S.
AU - Nahi, H.
AU - Cook, G.
AU - Mateos, M.-V.
AU - Rajkumar, S.V.
AU - Dimopoulos, M.A.
AU - Richardson, P.G.
JO - The lancet oncology
PY - 2021
VL - 22
TODO - 3
SP - e105-e118
PB - The Lancet Publishing Group
SN - null
TODO - 10.1016/S1470-2045(20)30756-7
TODO - bortezomib;  carfilzomib;  daratumumab;  dexamethasone;  doxorubicin;  elotuzumab;  idecabtagene vicleucel;  isatuximab;  lenalidomide;  melphalan;  panobinostat;  pomalidomide;  prednisone;  antineoplastic agent, cancer recurrence;  cancer survival;  clinical practice;  drug efficacy;  drug safety;  fatigue;  gastrointestinal disease;  health care policy;  high income country;  human;  intention to treat analysis;  low income country;  middle income country;  minimal residual disease;  multiple myeloma;  overall survival;  practice guideline;  progression free survival;  refractory multiple myeloma;  Review;  systematic review;  thrombocytopenia;  drug effect;  drug resistance;  multiple myeloma;  pathology;  salvage therapy;  tumor recurrence, Antineoplastic Agents;  Drug Resistance, Neoplasm;  Humans;  Multiple Myeloma;  Neoplasm Recurrence, Local;  Practice Guidelines as Topic;  Salvage Therapy
TODO - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes. © 2021 Elsevier Ltd
ER -